sequencing-based diagnostics
Caris Life Sciences Raises $830M to Support Precision Medicine Platform, Liquid Biopsy Development
The funds will help support Caris' ongoing commercial efforts in comprehensive cancer genomics as it makes new forays into liquid biopsy for multi-cancer early detection.
NantHealth Q1 Revenues Decline 11 Percent
NantHealth reported a net loss of $15.4 million during the quarter, as sequencing and molecular analysis revenues fell to just $3,000.
Korean Rare Disease Diagnostics Firm 3billion Looks to 2022 IPO, Expansion Into Drug Discovery
Premium
Fresh off a $13 million round of venture capital, the company said it sees global potential in analyzing hereditary conditions.
Rare Disease Screening Firm 3billion Closes $13M Series C Financing
The Korean molecular diagnostics firm, a spinoff from genomic services provider Macrogen
Twist Bioscience, Biotia Nab FDA EUA for Hybridization-Based NGS SARS-CoV-2 Assay
The hybridization-based test may provide better detection of emerging COVID-19 variants of concern, due to a higher tolerance for probe mismatches than in PCR.
Feb 25, 2021
NantHealth Q4 Revenues Flat From Year Ago
Feb 25, 2021
Feb 24, 2021
Adaptive Biotechnologies Q4 Revenues Rise 25 Percent
Nov 10, 2020
Adaptive Biotechnologies Q3 Revenues Grow 1 Percent
Nov 5, 2020